“To inform or not to inform,
that is the question.”
~ not quite Shakespeare but, apparently, the pharmaceutical industry
32,829 public reports
from gadolinium toxicity
However, patients who did a Freedom of Information Act pull in August 2016 revealed 33,000 reports with one singular GBCA product, Magnevist. How is it possible that, today, the total reported cases are fewer than those for one product nearly a decade ago? Could reports be lost or suppressed before reaching public awareness, akin to how one MRI contrast company reportedly instructed employees to “Burn the Data”? Or are these simply global reports? And how many cases are left unreported? How many countless individuals don’t have the information to acknowledge or recognize gadolinium as the cause of their illness?
FDA Adverse Event Reporting System (FAERS)
Total Reported
Every gadolinium-containing drug (we could find) in the database as of 12/10/2024
Gadoterate meglumine, Dotarem, Clariscan
Gadobutrol, Gadavist, Gadovist
Gadoteridol, ProHance
Gadopiclenol, Elucirem, Vueway
Gadopentetate dimeglumine, Magnevist
Gadobenate dimeglumine, Gadobenic acid, MultiHance
Gadoxetate disodium, gadoxetic acid, Eovist, Primovist
Gadodiamide, Omniscan
Gadoversetamide, OptiMARK
Gadofosveset trisodium, Ablavar (formerly Vasovist)
Gadolinium
Gadolinium chloride hexahydrate
Gadolinium oxide
Gadolinium zeolite
Motexafin gadolinium
See the breakdown for each individual brand of contrast:
